Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.130,63
0,38%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX) Notizie

Edgewise Therapeutics Inc

EWTX
19,52
0,23 (1,19%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
23/4/202414:00BWEdgewise Receives European Medicines Agency (EMA) Orphan..
15/4/202422:05BWEdgewise Therapeutics Announces Positive Two-Year Topline..
28/3/202413:00BWEdgewise Therapeutics Announces Upcoming Podium Presentation..
27/3/202413:00BWEdgewise Therapeutics to Present at the Cantor Virtual..
05/3/202414:00BWEdgewise Therapeutics to Present at the Leerink Partners..
28/2/202414:00BWEdgewise Therapeutics to Present on EDG-5506 for the..
22/2/202414:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202414:00EDGAR2Form 8-K - Current report
22/2/202414:00BWEdgewise Therapeutics Reports Fourth Quarter and Full Year..
14/2/202414:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202414:00BWEdgewise Receives U.S. FDA Fast Track Designation for..
09/2/202423:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:15EDGAR2Form 144 - Report of proposed sale of securities
19/1/202422:54EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/1/202414:44EDGAR2Form 8-K - Current report
19/1/202414:37BWEdgewise Therapeutics Announces Pricing of $240 Million..
19/1/202412:05EDGAR2Form 8-K - Current report
19/1/202412:04EDGAR2Form S-3MEF - Registration adding securities to prior Form..
19/1/202412:02EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
09/1/202414:39BWEdgewise Therapeutics Highlights 2023 Accomplishments and..
28/12/202322:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/12/202322:32EDGAR2Form 144 - Report of proposed sale of securities
19/12/202314:00BWEdgewise Therapeutics to Present at the 42nd Annual J.P...
18/12/202314:00BWEdgewise Therapeutics Launches First of Its Kind Educational..
30/11/202314:56DJNEdgewise Gets FDA Orphan, Rare-Pediatric-Disease..
30/11/202314:00BWEdgewise Receives Orphan Drug and Rare Pediatric Disease..
09/11/202314:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202314:00EDGAR2Form 8-K - Current report
09/11/202314:00BWEdgewise Therapeutics Reports Third Quarter 2023 Financial..
08/11/202314:00BWEdgewise Therapeutics to Present at Upcoming Investor..
01/11/202313:00BWEdgewise to Present Data on EDG-7500 at the American Heart..
26/10/202314:00BWEdgewise Therapeutics Announces Expansion of their EDG-5506..
27/9/202314:00BWEdgewise Therapeutics to Present on EDG-5506 for Becker..
26/9/202314:00BWEdgewise Therapeutics Announces Initiation of GRAND CANYON,..
14/9/202314:00BWEdgewise Therapeutics Begins Dosing First-in-Human Phase 1..
19/8/202301:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/8/202301:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202314:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202314:00EDGAR2Form 8-K - Current report
10/8/202314:00BWEdgewise Therapeutics Reports Second Quarter 2023 Financial..
14/7/202322:05EDGAR2Form 8-K - Current report
26/6/202322:01BWEdgewise Therapeutics Announces Positive 12-Month Topline..
06/6/202314:00BWEdgewise Therapeutics to Present at the Goldman Sachs Global..
11/5/202314:00BWEdgewise Therapeutics Reports First Quarter 2023 Financial..
Apertura: 19,74 Min: 19,44 Max: 20,12
Chiusura: 19,29

La tua Cronologia

NASDAQ
EWTX
Edgewise Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network